Table 1. Median (and range) plasma LH concentrations (μg/L).
* = min. after cKP10 administration.
| Group | Basal | t = 30 | t = 60 | t = 90 | t = 120 | t = 130 / t = 10* | t = 140 / t = 20* | t = 160 / t = 40* | t = 180 / t = 60* |
|---|---|---|---|---|---|---|---|---|---|
| controls | 1.8 (1.3–5.5) | n/a | n/a | n/a | n/a | 8.5 (5.1–26.8) | 5.2 (4.0–11.9) | 3.3 (2.5–5.2) | 2.5 (1.3–3.5) |
| p354 | 4.2 (2.8–6.7) | 3.7 (2.1–13.1) | 3.2 (2.2–7.2) | 3.6 (3.0–6.3) | 5.2 (2.6–15.7) | 13.5 (8.4–20.3) | 10.0 (5.5–13.0) | 6.4 (4.7–9.1) | 4.7 (3.7–9.9) |
| p356 | 4.3 (2.8–6.0) | 4.1 (2.4–12.8) | 3.9 (2.2–7.7) | 4.5 (2.8–6.7) | 4.9 (2.1–10.4) | 12.8 (9.1–23.1) | 8.7 (7.1–13.4) | 6.9 (3.7–12.8) | 4.7 (3.6–12.8) |
| p271 | 4.0 (2.9–5.9) | 3.9 (2.2–5.4) | 5.2 (2.5–10.0) | 4.5 (2.8–6.3) | 6.0 (3.2–7.5) | 16.2 (9.3–24.1) | 10.0 (5.7–12.6) | 6.4 (4.8–8.8) | 4.8 (3.5–7.3) |
Median and range of plasma LH concentrations before and during antagonist p271, p354, and p356 infusion. At t = 120 min canine KP10 (0.5 μg/kg) was administered intravenously. n = 6 dogs per group.